Incremental prognostic value of dobutamine-atropine stress 99mTc-tetrofosmin myocardial perfusion imaging for predicting outcome in diabetic patients with limited exercise capacity

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 32, Issue 9, 2005, Pages 1057-1063

  Pedone, Chiara ^a   Schinkel, Arend F L ^b   Elhendy, Abdou ^b   Van Domburg, Ron T ^b   Valkema, Roelf ^b   Biagini, Elena ^b   Simoons, Maarten L ^b   Bax, Jeroen J ^c   Poldermans, Don ^b  

^a BELLARIA HOSPITAL   (Italy)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

99mTc tetrofosmin; Diabetes mellitus; Prognosis; SPECT

Indexed keywords

ATROPINE; DOBUTAMINE; TETROFOSMIN TC 99M;

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; CONTROLLED STUDY; DIABETES MELLITUS; EXERCISE; EXERCISE TEST; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART INFARCTION; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HEART PERFUSION; HUMAN; IMAGING; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT; POPULATION; PREDICTION; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

AGE DISTRIBUTION; ATROPINE; COMORBIDITY; DIABETES MELLITUS; DOBUTAMINE; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NETHERLANDS; PROGNOSIS; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 25144518666     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1815-y     Document Type: Article

References (29)

1. American Diabetes Association. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes. Diabetes Care 1998;21:1551-9.
2. Grundy SM, Benjamin IJ, Burke GL, Chait A, Eckel RH, Howard BV, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation 1999;100:1134-46.
3. Rosamond WD, Chambless LE, Folsmon AR, Cooper LS, Conwill DE, Clegg L, et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987 to 1994. N Eng J Med 1998;339:861-7.
4. Gu K, Cowie CC, Harris MI. Diabetes and decline in heart disease mortality in US adults. JAMA 1999;281:1291-7.
5. Pyorala K, Pedersen TR, Kjeksus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
6. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of HOPE study and MICRO-HOPE sub study. Lancet 2000;355:253-9.
7. The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997;96:1761-9.
8. Felsher J, Meissner MD, Hakki AH, Heo J, Kane-March S. Iskandrian AS. Exercise thallium imaging in patients with diabetes mellitus. Arch Intern Med 1987;147:313-7.
9. Vanzetto G, Halimi S, Hammound T, Fagret D, Benhamou PY, Cordonnier D, et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Diabetes Care 1999;22:19-26.
10. Cohen MC, Curran PJ, L'Italien GJ, Mittelman MA, Zarich SW. Long-term prognostic value of preoperative dipyridamole thallium imaging and clinical indexes in patients with diabetes mellitus undergoing peripheral vascular surgery. Am J Cardiol 1999;83:1038-42.
11. Kang X, Berman DS, Lewin HC, Cohen I, Friedman JD, Germano G, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography in patients with diabetes mellitus. Am Heart J 1999;138:1025-32.
12. Giri S, Shaw LJ, Murthy DR, Travin MI, Miller DD, Hachamovitch R, et al. Impact of diabetes on risk stratification using stress single-photon emission computed tomography myocardial perfusion imaging in patients with symptoms suggestive of coronary artery disease. Circulation 2002;105:32-40.
13. De Lorenzo A, Lima RS, Siqueira-Filho AG, Pantoja MR. Prevalence and prognostic value of perfusion defects detected by stress technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography in asymptomatic patients with diabetes mellitus and no known coronary artery disease. Am J Cardiol 2002;90:827-32.
14. Schinkel AFL, Elhendy A, van Domburg RT, Bax JJ, Vourvouri EC, Sozzi FB, et al. Prognostic value of dobutamine-atropine stress myocardial perfusion imaging in patients with diabetes. Diabetes Care 2002;25:1637-43.
15. 201Tl imaging and coronary angiography in a phase III multicenter trial. Circulation 1995;91:313-9.
16. Jain D, Wackers FJ, Mattera J, McMahon M, Sinusas AJ, Zaret BL. Biokonetics of technetium-99m-tetrofosmin: myocardial perfusion imaging agent: implications for one day imaging protocol. J Nucl Med 1993;34:1254-9.
17. Handel RC, Parker MA, Wackers FJ, Rigo P, Lahiri A, Zaret BL. Reduced variability of interpretation and improved image quality with technetium-99m myocardial perfusion agent: comparison of thallium 201 and technetium-99m labeled tetrofosmin. J Nucl Cardiol 1994;1:509-14.
18. Shanoudy H , Raggi P, Beller GA, Soliman A, Ammermann EG, Kastner RJ, et al. Comparison of technetium-99m tetrofosmin and thallium-201 single photon emission computer tomographic imaging for detection of myocardial perfusion defects in patients with coronary artery disease. J Am Coll Cardiol 1998;31:331-7.
19. Rigo P, Leclercq B, Itti R, Lahiri A, Braat S. Technetium-99m-tetrofosmin myocardial imaging: a comparison with thallium-201 and angiography. J Nucl Med 1994;35:587-93.
20. Elhendy A, Bax JJ, Poldermans D. Dobutamine stress myocardial perfusion imaging in coronary artery disease. J Nucl Med 2002;43:1634-46.
21. Hachamovitch R, Berman DS, Kiat H, Cohen I, Cabico JA, Friedman J, et al. Exercise myocardial perfusion SPECT in patients without known coronary artery disease: incremental prognostic value and use in risk stratification. Circulation 1996;93:905-14.
22. 99mTc-tetrofosmin myocardial perfusion SPECT in patients with known or suspected coronary artery disease. J Nucl Med 2002;43:767-72.
23. Cox DR. Regression models and life-tables. J R Stat Soc (B) 1972;34:187-202.
24. Soman P, Taillefer R, DePuey EG, Udelson JE, Lahiri A. Enhanced detection of reversible perfusion defects by Tc-99m sestamibi compared to Tc-99m tetrofosmin during vasodilator stress SPECT imaging in mild-to-moderate coronary artery disease. J Am Coll Cardiol 2001;37:458-62.
25. 201Tl and regional myocardial blood flow. Circulation 1997;96:2332-8.
26. 99mTc-tetrofosmin SPECT imaging: results from the multicenter registry of 4,728 patients. J Nucl Med 2003;44:134-9.
27. Iskander S, Iskandrian AE. Risk assessment using single-photon emission computer tomographic technetium-99m sestamibi imaging. J Am Coll Cardiol 1998;32:57-62.
28. Galassi AR, Azzarelli S, Tomaselli A, Giosofatto R, Ragusa A, Masumeci S, et al. Incremental prognostic value of technetium-99m-tetrofosmin exercise myocardial perfusion imaging of predicting outcomes in patients with suspected or known coronary disease. Am J Cardiol 2001;88:101-6.
29. Schinkel AFL, Elhendy A, van Domburg RT, Bax JJ, Vourvouri EC, Bountioukos M, et al. Incremental value of exercise technetium-99m tetrofosmin myocardial perfusion single-photon emission tomography for the prediction of cardiac events. Am J Cardiol 2003;91:408-11.